Treatment for glioblastoma (GBM)
Intended for US audiences only.

The NovoTAL System

Optimize treatment with Optune using the FDA‐approved NovoTAL System

  • In electric field simulation studies, it was possible to achieve a substantial increase in Tumor Treating Fields (TTFields) intensity to a specific region of the brain by adapting the configuration of paired arrays1

Individualize Optune for every patient

  • Treatment planning is an essential component of therapy with Optune

  • The NovoTAL System is utilized to create individualized treatment maps for all clinical and commercial patients starting Optune

To learn more about the NovoTAL System, please email

NovoTAL system transducer array layout
NovoTAL system view form

Reference: 1. Wenger C, Salvador R, Basser PJ, Miranda PC. Improving Tumor Treating Fields treatment efficacy in patients with glioblastoma using personalized array layouts. Int J Radiat Oncol Biol Phys, 2016;94(5):1137e1143.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).